Cerulean Pharma (CERU) Says CRLX101 Combo Phase 2 Missed Primary Endpoint
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 4/19/2024
- Nasdaq lags peers as Netflix, chip stocks drag; AmEx lifts Dow
- Sony/Apollo bid for Paramount could be worth as much as $29 billion - Source
- Netflix Q1 earnings top estimates on blowout subscriber growth
- Wall St indexes split, Treasuries dip amid earnings, geopolitical crosscurrents
- Gold prices rally past $2,400 on reports of Israel strikes on Iran
- Tritium DCFC Limited (DCFC): Three Australian subsidiaries were determined to be insolvent or likely to become insolvent
- Hasbro (HAS) Announces Resignation of Cynthia Williams, President of Wizards of the Coast and Hasbro Gaming
- Frontier Communications (FYBR) says third party had gained unauthorized access to portions of its information technology environment
- Jabil falls after placing CEO on paid leave amid internal investigation
- Ibotta (IBTA) Prices 6.56M Share IPO at $88/sh
- Midday movers: Netflix, Super Micro fall; Paramount Global gains
- After-hours movers: Netflix, Intuitive Surgical, Nordstrom, KB Home
- Midday movers: Tesla, Blackstone, Las Vegas Sands fall; DR Horton rises
- After-hours movers: Alcoa rises; Equifax and Las Vegas Sands fall
- Midday movers: Travelers, JB Hunt fall; United Airlines rises
Wedbush Downgrades Cerulean Pharma (CERU) to Neutral
August 18, 2016 2:58 PM EDTWedbush earlier downgraded Cerulean Pharma (NASDAQ: CERU) from Outperform to Neutral with a price target of $1.00 (from $9.00).
For an analyst ratings summary and ratings history on Cerulean Pharma click here. For more ratings news on Cerulean Pharma click here.
Shares of Cerulean Pharma closed at $2.74 yesterday.
... MoreLeerink Partners Downgrades Cerulean Pharma (CERU) to Market Perform
August 18, 2016 7:29 AM EDTLeerink Partners downgraded Cerulean Pharma (NASDAQ: CERU) from Outperform to Market Perform with a price target of $1.50 (from $8.00). The change follows disappointed CRLX-101 trial results.
"We are downgrading CERU to MP following the failure of lead product candidate CRLX-101 (camptothecin nanoparticle-drug conjugate/NDC) in a... More
Janney Montgomery Scott Downgrades Cerulean Pharma (CERU) to Neutral
August 18, 2016 6:32 AM EDTJanney Montgomery Scott downgraded Cerulean Pharma (NASDAQ: CERU) from Buy to Neutral with a price target of $1.00 (from $6.00).
For an analyst ratings summary and ratings history on Cerulean Pharma click here. For more ratings news on Cerulean Pharma click here.
Shares of Cerulean Pharma closed at $2.74 yesterday.
... MoreRoth Capital Cuts PT on Cerulean Pharma (CERU) to $2.50 Following CRLX101 Combo Phase 2 Data
August 18, 2016 6:29 AM EDTRoth Capital cuts its price target on Buy-rated Cerulean Pharma (Nasdaq: CERU) from $9 to $2.50 after the company announced top-line results from the Companys Phase 2, randomized, multi-center clinical trial of its lead candidate, CRLX101, in combination with Avastin (bevacizumab) in the treatment of patients with advanced renal cell carcinoma (RCC).
Analyst Joseph Pantginis commented, HIF directed studies will be terminated and the topoisomerase directed studies will become the primary focus. CERU... More
